These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29507054)

  • 1. Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.
    Azimi A; Caramuta S; Seashore-Ludlow B; Boström J; Robinson JL; Edfors F; Tuominen R; Kemper K; Krijgsman O; Peeper DS; Nielsen J; Hansson J; Egyhazi Brage S; Altun M; Uhlen M; Maddalo G
    Mol Syst Biol; 2018 Mar; 14(3):e7858. PubMed ID: 29507054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
    Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
    Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.
    Rebecca VW; Wood E; Fedorenko IV; Paraiso KH; Haarberg HE; Chen Y; Xiang Y; Sarnaik A; Gibney GT; Sondak VK; Koomen JM; Smalley KS
    Mol Cell Proteomics; 2014 Jul; 13(7):1844-54. PubMed ID: 24760959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
    Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
    Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.
    Haarberg HE; Paraiso KH; Wood E; Rebecca VW; Sondak VK; Koomen JM; Smalley KS
    Mol Cancer Ther; 2013 Jun; 12(6):901-12. PubMed ID: 23538902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?
    Catalanotti F; Solit DB
    Clin Cancer Res; 2012 May; 18(9):2420-2. PubMed ID: 22442059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling.
    Desai BM; Villanueva J; Nguyen TT; Lioni M; Xiao M; Kong J; Krepler C; Vultur A; Flaherty KT; Nathanson KL; Smalley KS; Herlyn M
    PLoS One; 2013; 8(3):e59588. PubMed ID: 23527225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
    Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
    Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
    Haq R; Yokoyama S; Hawryluk EB; Jönsson GB; Frederick DT; McHenry K; Porter D; Tran TN; Love KT; Langer R; Anderson DG; Garraway LA; Duncan LM; Morton DL; Hoon DS; Wargo JA; Song JS; Fisher DE
    Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4321-6. PubMed ID: 23447565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
    Kundu A; Quirit JG; Khouri MG; Firestone GL
    Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
    Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
    Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
    Wellbrock C; Rana S; Paterson H; Pickersgill H; Brummelkamp T; Marais R
    PLoS One; 2008 Jul; 3(7):e2734. PubMed ID: 18628967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer.
    Abdalla AN; Qattan A; Malki WH; Shahid I; Hossain MA; Ahmed M
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33050377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HSP90 inhibitor, XL888, enhanced cell apoptosis via downregulating STAT3 after insufficient radiofrequency ablation in hepatocellular carcinoma.
    Sun C; Bai M; Ke W; Wang X; Zhao X; Lu Z
    Life Sci; 2021 Oct; 282():119762. PubMed ID: 34186047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MITF-independent pro-survival role of BRG1-containing SWI/SNF complex in melanoma cells.
    Ondrušová L; Vachtenheim J; Réda J; Záková P; Benková K
    PLoS One; 2013; 8(1):e54110. PubMed ID: 23349796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF.
    Liu X; Li Z; Li M; Chai J; He S; Wu J; Xu J
    Oncol Rep; 2020 Jul; 44(1):360-370. PubMed ID: 32319656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.
    Gopal YN; Rizos H; Chen G; Deng W; Frederick DT; Cooper ZA; Scolyer RA; Pupo G; Komurov K; Sehgal V; Zhang J; Patel L; Pereira CG; Broom BM; Mills GB; Ram P; Smith PD; Wargo JA; Long GV; Davies MA
    Cancer Res; 2014 Dec; 74(23):7037-47. PubMed ID: 25297634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined BRAF and HSP90 Inhibition in Patients with Unresectable
    Eroglu Z; Chen YA; Gibney GT; Weber JS; Kudchadkar RR; Khushalani NI; Markowitz J; Brohl AS; Tetteh LF; Ramadan H; Arnone G; Li J; Zhao X; Sharma R; Darville LNF; Fang B; Smalley I; Messina JL; Koomen JM; Sondak VK; Smalley KSM
    Clin Cancer Res; 2018 Nov; 24(22):5516-5524. PubMed ID: 29674508
    [No Abstract]   [Full Text] [Related]  

  • 20. Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors.
    Abdalla AN; Abdallah ME; Aslam A; Bader A; Vassallo A; Tommasi N; Malki WH; Gouda AM; Mukhtar MH; El-Readi MZ; Alkahtani HM; Abdel-Aziz AA; El-Azab AS
    Molecules; 2020 May; 25(9):. PubMed ID: 32397330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.